Lorlatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. It is used as a first-line treatment or after disease progression on prior ALK inhibitor therapy, providing a powerful option for patients with ALK-driven lung cancer.
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor that works by selectively blocking the activity of anaplastic lymphoma kinase (ALK) and ROS1 proteins. By inhibiting these kinases, it prevents the signaling pathways that drive cancer cell growth and proliferation, including resistance mutations that may develop during treatment with earlier-generation ALK inhibitors.
The recommended dosage is 100 mg taken orally once daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity. Dose modifications may be required based on individual patient tolerability.